feedback

Course Director

Farhad Ravandi, MD
Farhad Ravandi, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Michael R. Savona
Michael R. Savona, MD

Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Amir T. Fathi
Amir T. Fathi, MD

Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Naval Daver
Naval Daver, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2016-Dec-23
Expiration Date:2017-Dec-22
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

While the current standard of care in acute myeloid leukemia (AML)—cytarabine-based chemotherapy—may be an effective option for many patients, others are unlikely to benefit from this intensive strategy; this fact has prompted much clinical research into new and novel options for AML treatment, a search that may now be bearing fruit. Currently, a number of therapeutic advances, driven in part by a modern understanding of AML biology, are on the cusp of validation. This CME activity, based on an expert-driven symposium held prior to the 2016 ASH annual meeting, will feature important science on a growing wave of new options for AML, including next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents; in addition, the experts will discuss what the validation of such strategies might mean for practice, and highlight the most important ongoing clinical trials in the field, offering key insight on which patients with AML should be considered candidates for trials that may rapidly change medical care. The experts will also provide insight on how minimal residual disease eradication may be one important measure of the efficacy of newer therapeutics in the years to come.

Upon completion of this activity, participants should be better able to:
  • Identify newly described molecular features and anticancer mechanisms of therapeutic potential in AML, including for novel targeted and immunotherapeutic agents
  • Discuss updated evidence on the clinical role and efficacy of emerging therapeutic options and agent classes in AML, including targeted therapies, immunotherapies, and other strategies
  • Summarize safety considerations with novel therapeutics currently being tested in patients with AML
  • Recognize patients with AML unlikely to benefit from standard chemotherapy-based protocols who are candidates for alternative therapeutic options
  • Recommend therapy, including in the context of a clinical trial, with novel components for patients with AML who may not benefit from standard therapy

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, medical oncologists, advanced practice oncology nurses, oncology physician assistants, and other healthcare professionals involved in the care of patients with acute myeloid leukemia.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 23, 2016 - December 22, 2017
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.

Course Director and Moderator
Farhad Ravandi, MD
Janiece and Stephen A. Lasher Professor of Medicine
Chief, Section of Developmental Therapeutics
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.
Grant/Research Support from Amgen Inc.; Bristol-Myers Squibb; Seattle Genetics; Sunesis Pharmaceuticals; and Xencor, Inc.
Honorarium from Xencor, Inc.
Advisory Board for Astex Pharmaceuticals Inc.; Karyopharm Therapeutics; Seattle Genetics; and Sunesis Pharmaceuticals.

Farhad Ravandi, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: A number of therapeutic options for acute myeloid leukemia (AML), including novel cytotoxic, targeted, and immunotherapeutic strategies.

Faculty
Michael R. Savona, MD
Director of Hematology Research
Associate Professor of Medicine
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Michael R. Savona, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Astex Pharmaceuticals; Incyte Corporation; Takeda Pharmaceuticals U.S.A., Inc.; and TG Therapeutics, Inc.
Shareholder in Karyopharm Therapeutics.
Advisory Board for Amgen Inc.; Baxalta; and Karyopharm Therapeutics.
Other Financial or Material Support from Data and Safety Monitoring Board (DSMB) and Data Monitoring Committee (DMC) for Celgene Corporation and Gilead.

Michael R. Savona, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: A number of therapeutic options for acute myeloid leukemia (AML), including novel cytotoxic, targeted, and immunotherapeutic strategies.

Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Agios Pharmaceuticals, Inc.; Baxalta; Celgene Corporation; and Seattle Genetics.
Advisory Board for Agios Pharmaceuticals, Inc.; Baxalta; Merck & Co., Inc.; and Seattle Genetics.

Amir T. Fathi, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: A number of therapeutic options for acute myeloid leukemia (AML), including novel cytotoxic, targeted, and immunotherapeutic strategies.

Naval Daver, MD
Assistant Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Novartis Pharmaceuticals Corporation and Otsuka America Pharmaceutical, Inc.
Grant/Research Support from ARIAD Pharmaceuticals, Inc.; Bristol-Myers Squibb; Incyte Corporation; Karyopharm Therapeutics; Kiromic; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Sunesis Pharmaceuticals, Inc.
Advisory Board for Astex Pharmaceuticals; ImmunoGen, Inc.; Incyte Corporation; Karyopharm Therapeutics; Novartis Pharmaceuticals Corporation; and Sunesis Pharmaceuticals, Inc.

Naval Daver, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: A number of therapeutic options for acute myeloid leukemia (AML), including novel cytotoxic, targeted, and immunotherapeutic strategies.

CME Reviewer
Amer Assal, MD
Columbia University Medical Center
Blood and Marrow Transplantation Program
New York, New York

Amer Assal, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AbbVie, Astellas Pharma Global Development, Inc., Karyopharm Therapeutics, and Seattle Genetics.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2016, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.